蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
楼主: 毒手药王
收起左侧

[药品研发] (中英文对照)开启片剂完整性的窗户

  [复制链接]
药徒
发表于 2014-12-7 14:11:24 | 显示全部楼层
谢谢楼主的分享!
回复

使用道具 举报

发表于 2014-12-8 09:04:05 | 显示全部楼层
谢谢分享好好学习一下
回复

使用道具 举报

药徒
发表于 2014-12-8 11:20:13 | 显示全部楼层
这是神马?
回复

使用道具 举报

药徒
发表于 2014-12-8 11:37:44 | 显示全部楼层
谢谢楼主分享
回复

使用道具 举报

发表于 2015-3-4 10:06:28 | 显示全部楼层

谢谢楼主分享
回复

使用道具 举报

发表于 2015-3-4 11:05:30 | 显示全部楼层
学习学习!
回复

使用道具 举报

发表于 2015-3-10 21:36:28 | 显示全部楼层
先看一看。
回复

使用道具 举报

发表于 2015-3-10 21:36:59 | 显示全部楼层
下了,谢啦。
回复

使用道具 举报

发表于 2015-3-19 17:14:24 | 显示全部楼层
看看是什么
回复

使用道具 举报

发表于 2015-3-19 19:31:28 | 显示全部楼层
学习一下!
回复

使用道具 举报

药徒
发表于 2015-3-19 19:48:04 | 显示全部楼层
好好呀,O(∩_∩)O哈哈哈~
回复

使用道具 举报

药徒
发表于 2015-3-19 20:07:44 | 显示全部楼层
学习一下,谢谢
回复

使用道具 举报

药徒
发表于 2015-3-20 21:06:47 | 显示全部楼层
先回复再下载
回复

使用道具 举报

药徒
发表于 2015-3-21 13:31:25 | 显示全部楼层


Ceftriaxone Sodium
(sef'' trye ax' one soe' dee um).
Click to View Image
C18H16N8Na2O7S3·3½H2O 661.60

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5-, 6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, [6R-[6,7(Z)]]-, hydrate, (2:7).

(6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-(O-methyloxime), disodium salt, sesquaterhydrate [104376-79-6].

Anhydrous 598.56
» Ceftriaxone Sodium contains the equivalent of not less than 795 μg of ceftriaxone (C18H18N8O7S3) per mg, calculated on the anhydrous basis.
Packaging and storage— Preserve in tight containers.
Labeling— Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.
USP Reference standards 11—
USP Ceftriaxone Sodium RS
USP Ceftriaxone Sodium E-Isomer RS
USP Endotoxin RS
Identification—
A: Infrared Absorption 197K.
B: The chromatogram of the Assay preparation obtained as directed in the Assay exhibits a major peak for ceftriaxone, the retention time of which corresponds to that exhibited in the chromatogram of the Standard preparation obtained as directed in the Assay.
C: It responds to the tests for Sodium 191.
Crystallinity 695: meets the requirements.
pH 791: between 6.0 and 8.0 in a solution (1 in 10).
Water, Method I 921: between 8.0% and 11.0%.
Other requirements— Where the label states that Ceftriaxone Sodium is sterile, it meets the requirements for Sterility and Bacterial endotoxins under Ceftriaxone for Injection. Where the label states that Ceftriaxone Sodium must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements for Bacterial endotoxins under Ceftriaxone for Injection.
Assay—
pH 7.0 Buffer— Dissolve 13.6 g of dibasic potassium phosphate and 4.0 g of monobasic potassium phosphate in water to obtain 1000 mL of solution. Adjust this solution with phosphoric acid or 10 N potassium hydroxide to a pH of 7.0 ± 0.1.
pH 5.0 Buffer— Dissolve 25.8 g of sodium citrate in 500 mL of water, adjust with citric acid solution (1 in 5) to a pH of 5.0 ± 0.1, and dilute with water to a volume of 1000 mL.
Mobile phase— Dissolve 3.2 g of tetraheptylammonium bromide in 400 mL of acetonitrile, add 44 mL of pH 7.0 Buffer and 4 mL of pH 5.0 Buffer, and add water to make 1000 mL. Filter through a membrane filter of 0.5 μm or finer porosity, and degas. Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Dissolve an accurately weighed quantity of USP Ceftriaxone Sodium RS in Mobile phase, to obtain a solution having a known concentration of about 0.2 mg per mL. Use this solution promptly after preparation.
Resolution solution— Dissolve a suitable quantity of USP Ceftriaxone Sodium E-Isomer RS in Standard preparation, and dilute with Mobile phase to obtain a solution containing about 160 μg of USP Ceftriaxone Sodium E-Isomer RS per mL and 160 μg of USP Ceftriaxone Sodium RS per mL. Use this solution promptly after preparation.
Assay preparation— Transfer about 40 mg of Ceftriaxone Sodium, accurately weighed, to a 200-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix. Use this solution promptly after preparation.
Chromatographic system (see Chromatography 621)—The liquid chromatograph is equipped with a 270-nm detector and a 4.0-mm × 15-cm column that contains 5-μm packing L1. The flow rate is about 2 mL per minute. Chromatograph the Resolution solution, and record the peak responses as directed under Procedure: the resolution, R, between the ceftriaxone E-isomer and ceftriaxone peaks is not less than 3. Chromatograph the Standard preparation, and record the peak responses as directed under Procedure: the column efficiency determined from the analyte peak is not less than 1500 theoretical plates; the tailing factor for the analyte peak is not more than 2; and the relative standard deviation for replicate injections is not more than 2%.
Procedure— Separately inject equal volumes (about 20 μL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in μg, of ceftriaxone (C18H18N8O7S3) per mg of the Ceftriaxone Sodium taken by the formula:
200(CP / W)(rU / rS)
in which C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in the Standard preparation; P is the designated potency, in μg of ceftriaxone per mg, of USP Ceftriaxone Sodium RS; W is the quantity, in mg, of the Ceftriaxone Sodium taken to prepare the Assay preparation; and rU and rS are the ceftriaxone peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question        Contact        Expert Committee
Monograph        Ahalya Wise, M.S.
Senior Scientific Liaison
1-301-816-8161        (SM12010) Monographs - Small Molecules 1
Reference Standards        RS Technical Services
1-301-816-8129
rstech@usp.org       
USP35–NF30 Page 2576


此网站为英文页面, 是否需要翻译?×不再翻译此网站人工翻译
回复

使用道具 举报

发表于 2015-3-21 13:38:38 | 显示全部楼层
整性的窗户(中
回复

使用道具 举报

药徒
发表于 2015-3-21 13:51:33 | 显示全部楼层
信息。。。。。。。。
回复

使用道具 举报

药徒
发表于 2015-3-28 10:40:57 | 显示全部楼层
谢谢分享  值得学习哦
回复

使用道具 举报

药徒
发表于 2015-3-28 10:55:33 | 显示全部楼层
是甚法规?下载学习,谢谢分享。
回复

使用道具 举报

发表于 2015-3-28 14:24:51 | 显示全部楼层
好想学学习习
回复

使用道具 举报

药徒
发表于 2015-4-4 20:33:36 | 显示全部楼层
谢谢分享,,谢谢
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( (京)-非经营性-2014-0058 京ICP证150354号 京ICP备14042168号-1 )

GMT+8, 2024-3-29 09:25

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表